Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
I-MAB Filed 2023 Annual Report on Form 20-F
2024-04-30 19:00
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
2024-04-05 19:00
I-Mab Announces Closing of the Divestiture of Business Operations in China
2024-04-03 04:01
I-Mab Reports Full Year 2023 Financial Results and Business Update
2024-03-15 05:00
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
2024-02-07 19:00
I-Mab Announces Participation at Jefferies and Piper Conferences in November
2023-11-06 21:00
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
2023-11-02 20:00
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
2023-11-01 20:00
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
2023-10-16 20:00
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
2023-10-10 20:00
I-Mab Announces Upcoming Participation at September Conferences
2023-09-05 20:00
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
2023-08-17 18:00
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
2023-08-08 20:00
I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC
2023-07-05 20:00
I-Mab Announces the Appointment of Raj Kannan as CEO
2023-06-22 20:00
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023
2023-05-26 05:01
I-MAB Filed 2022 Annual Report on Form 20-F
2023-05-01 20:00
I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023
2023-04-26 21:16
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon
2023-04-25 13:46
I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China
2023-04-24 21:00
1
2
3
4
5
7